Le Lézard
Classified in: Health, Science and technology
Subject: ANNUAL MEETINGS

Greenrose Acquisition Corp. Sets Special Shareholder Meeting to Vote on Proposed Business Combination for October 27, 2021 at 9:00 A.M. Eastern Time


AMITYVILLE, N.Y., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Greenrose Acquisition Corp. (OTC: GNRSU, GNRS, GNRSW) ("Greenrose" or the "Company"), a special purpose acquisition company targeting companies in the cannabis industry, announced that it has filed its definitive proxy statement (the "Proxy Statement") relating to its previously announced proposed business combination (the "Business Combination") and set the time and date of 9:00 a.m. (Eastern Time) on October 27, 2021 for its special shareholder meeting to vote on the Business Combination ("Special Meeting"). The Proxy Statement is being mailed on or about October 5, 2021 to Greenrose's shareholders of record as of the close of business on September 23, 2021.

Greenrose's Business Combination will comprise its proposed merger with Connecticut-based Theraplant, LLC and the acquisition of certain assets of Arizona-based True Harvest, LLC (each a "Business Combination Transaction"). It is expected that the Company will proceed with its planned mergers with each of Shango Holdings, Inc. (Shango) and Futureworks LLC (d/b/a The Health Center) at a later date due to the time required to obtain state regulatory approvals.

If each Business Combination Transaction proposal is approved at the Special Meeting, the parties anticipate that the Business Combination will close on or about November 1, 2021, subject to the satisfaction or waiver (as applicable) of all other closing conditions.

Upon closing the Business Combination, the combined company will be named The Greenrose Holding Company and will continue to be listed on the OTC under the symbols "GNRSU," "GNRS," and "GNRSW." Greenrose also intends to list on the NEO exchange as soon as practicable after the close of the Business Combination.

About Greenrose
Greenrose Acquisition Corp. is a blank check company organized for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. Greenrose has entered into definitive agreements to acquire four cannabis companies, known collectively as "The Platform." The companies are Shango Holdings Inc. (Shango), Futureworks LLC (d/b/a The Health Center), Theraplant, LLC and True Harvest, LLC. The new Greenrose Platform will be a multistate operator that will look to further vertically and horizontally integrate in the markets that it is in and to enter new high growth and limited license markets.

Investor Relations Contact:
Gateway Investor Relations
Cody Slach or Jackie Keshner
(949) 574-3860
[email protected]

Greenrose Contact:
Daniel Harley
Executive Vice President, Business Development
(516) 307-0383
[email protected]



These press releases may also interest you

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase Ib clinical trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes. The...

at 00:00
Author Kory L. Wilson and his family have experienced the benefits of information he shares in Home Remedies: A Guidebook To Breaking Away From Big Pharma ($15.99, paperback, 9781662896668; $6.99, e-book, 9781662896675). For years, I have collected...

15 mai 2024
Full year 2023 revenue of $90.9 million compared to $99.4 million in 2022, and $90.5 million compared to $86.7 million on a normalized basis, excluding one-time COVID mandates.Q4 2023 gross profit margin1 of 39.7% was relatively flat compared to Q3...

15 mai 2024
On 13 May 2024, Fortune China magazine released the 2024 China ESG Impact List, and Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) was included in the list, highlighting its outstanding performance and...

15 mai 2024
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the latest results from five studies have been selected for...

15 mai 2024
Bristol Myers Squibb today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment...



News published on and distributed by: